Call to Schedule Free Consultation at Over 80 Centers Worldwide!

(844) GET-STEM

What Is the Most Successful Treatment for Multiple Sclerosis (MS)?

Written by Dr. David Greene, MD, PhD, MBA on November 2, 2026

Table of Contents

If you or someone you love has multiple sclerosis, you’ve probably asked this question and found conflicting answers. Some websites promise reversal. Others say nothing works. The honest answer is in between, and it matters most for anyone researching stem cell therapy for multiple sclerosis.

No single treatment is “most successful” for everyone. For most people with relapsing MS, a high-efficacy disease-modifying therapy (DMT) is the proven first choice. Among stem cell approaches, only one has strong evidence behind it: autologous hematopoietic stem cell transplantation (aHSCT), and only for carefully selected patients. Other stem cell and exosome treatments are still being studied. You can read more on our pages about stem cell therapy for multiple sclerosis and how stem cell therapy is used in MS.

How do we measure whether an MS treatment is successful?

“Success” means different things depending on who you ask. Researchers usually look at:

Relapse rate: how often symptoms flare up

MRI activity: whether new or enlarging lesions appear

Disability progression: whether function worsens over time

“No evidence of disease activity” (NEDA): no relapses, no new lesions and no worsening disability

For you, success may also mean being able to keep working, walking or caring for your family. A treatment that reduces relapses may still leave fatigue or cognitive symptoms untouched, so it’s worth asking your neurologist which outcome matters most for your situation.

Standard treatment: high-efficacy disease-modifying therapies

Most people with relapsing MS are treated with a DMT, and the stronger options include medicines such as ocrelizumab, natalizumab, alemtuzumab and cladribine. These drugs are approved, widely studied and monitored in routine practice. They are the benchmark any newer therapy has to beat. If you’re newly diagnosed, this is almost always where the conversation starts.

Stem cell therapy for multiple sclerosis: three different treatments

The phrase “stem cell therapy” covers very different things, and mixing them up is where many patients get misled.

1. aHSCT (autologous hematopoietic stem cell transplantation)

This is the stem cell treatment with the best evidence. Your own blood-forming stem cells are collected and stored, chemotherapy removes much of your immune system, and the stored cells are returned to rebuild it. The goal is to “reset” the immune attack on the nervous system. For more on the procedure itself, see our guide to the stem cell transplant process.

What the evidence says:

Trials so far suggest that for relapsing MS, or progressive MS with signs of active inflammation, aHSCT may stop or slow progression, reducing new lesions and relapses.

One review reports NEDA rates of 70% to 90% with transplant, versus about 50% with other MS therapies.

The benefit doesn't last for everyone, and worsening can occur in later years.

It doesn't regenerate damaged nerves. It targets inflammation, not existing damage.

Who is it for? The strongest results are in people with highly active relapsing MS who haven’t responded to, or can’t take, high-efficacy DMTs. They are usually under 50, with MS for no more than 10 years and low to moderate disability. The National MS Society takes a similar position, saying aHSCT may be useful for relapsing MS with substantial breakthrough disease activity despite high-efficacy treatment.

Who should be cautious? For people with progressive MS who show no inflammation and have high levels of disability, aHSCT is unlikely to help and carries added risk.

2. Mesenchymal stem cell (MSC) therapy

MSCs are adult stem cells, often taken from bone marrow, fat or umbilical cord tissue. They don’t require chemotherapy, and they’re studied for their ability to calm immune activity (see how mesenchymal stem cells interact with the immune system). The evidence for MS is still early:

Early small trials reported no serious adverse events, but there isn't yet enough evidence to say whether MSCs help people with MS at all.

The international MESEMS trial found MSC therapy safe and well tolerated, but not effective at reducing inflammation in active MS.

The MS International Federation says MSC therapy should only be offered as part of a clinical trial.

You can follow current research on our page about stem cell therapy and MS clinical trials.

3. Exosomes and intranasal approaches

Exosomes are tiny signaling vesicles released by cells. They’re a rapidly growing area of regenerative research, but human evidence in MS is limited. If you want the background, read our guide to exosomes, exosomes vs. stem cells and what our published research shows on intranasal delivery. Treat patient stories as stories, not as proof of effect. A person improving after a treatment doesn’t show the treatment caused it, because MS naturally fluctuates.

Delivery Modalities: Intravenous (IV) vs. Intranasal Delivery

In advanced neurological protocols, delivery method dictates biological distribution:

Body-Mass Calibrated IV Infusion: Systemic administration targets the systemic immune apparatus and circulating autoimmune cytokines. Calibrating cell doses to total body mass ensures uniform, therapeutic bioavailability.

Targeted Intranasal Administration: The blood-brain barrier remains a major hurdle for large biologics. Using specialized intranasal catheters (such as a SphenoCath) or aerosolized inhalation systems, providers deliver high-potency exosome therapy and cell-secreted factors across the cribriform plate via the olfactory and trigeminal nerve pathways directly into cerebral tissues.

Discover more details on non-invasive central nervous system delivery in our report on intranasal stem cell and exosome therapy.

Comparison of Leading MS Treatments

Treatment

Best For

Primary Objective

Typical Outcomes

High-Efficacy DMTs (e.g., Ocrelizumab)

Early relapsing MS

Reduce relapses and new MRI lesions

50–70% reduction in relapses; minimal impact on past damage

aHSCT (Immune Reset)

Aggressive relapsing MS non-responsive to DMTs

Reset the immune system via chemotherapy

High durable remission rates; higher toxicity and risk

MSCs & Exosomes

Relapsing & progressive MS (SPMS/PPMS)

Modulate inflammation and provide neuroprotection

Potential functional gains in mobility, coordination, and clarity

Realistic Expectations: Functional Recovery vs. "The Cure"

Transparency is essential when evaluating advanced medical interventions:no treatment available today provides a definitive, permanent cure for multiple sclerosis.

For patients with progressive disability, clinical success is defined by meaningful, day-to-day functional improvements:

Mobility Transitions: Patients who have used a wheelchair for years regaining the physical stability, motor control, and leg strength necessary to transition to walking with a cane or walker.

Reversing Cognitive Fatigue: Clearing neuroinflammatory "brain fog" to help patients regain focus, processing speed, and sustained memory.

Energy and Motor Coordination: Calming spasticity and tremor severity so individuals can manage daily self-care tasks independently.

Bladder and Bowel Control: Restoring autonomic nerve signaling to alleviate embarrassing incontinence or urinary urgency.

To evaluate broader patient experiences, read our collection of real-world regenerative medicine success stories and examine how providers approach autoimmune disease patients receiving stem cell therapy.

Regulatory Access: The Right to Try Act and International Care

Navigating regenerative therapy options can feel complicated due to regional differences in regulatory policies:

United States & The Right to Try Law: Under the federal Right to Try Act, eligible patients who have exhausted conventional options gain legal avenues to access investigational treatments that have completed Phase I safety trials. This legislation enables qualifying MS patients to receive cell and exosome interventions domestically across accredited regenerative facilities.

International Centers of Excellence: For specialized, high-dose combination protocols (including expanded cell counts and intrathecal administration options ), patients frequently choose established international hubs in Mexico or Pakistan that operate under local health department clinical approvals.

Review regulatory specifics and safety protocols in our comprehensive guide to understanding stem cell regulations and research and our checklist on how to choose the right stem cell clinic.

Steps to Determine the Best MS Treatment for You

You may be someone worth evaluating for regenerative therapy if you:

Classify Your Current Disease State: Confirm through recent neuroimaging whether your MS exhibits active gadolinium-enhancing inflammation or non-relapsing progression (SPMS/PPMS).

Review Your Treatment History: If conventional DMTs fail to halt symptoms or trigger debilitating side effects, consult your neurologist about second-line escalations or investigational regenerative programs.

Vet Biologic Quality: If pursuing stem cell or exosome therapy, ensure the laboratory conducts certified infectious disease testing, maintains strict viability and sterility controls, and doses precisely by body weight.

Integrate Physical Rehabilitation: Cellular therapies stimulate receptive biological windows; pairing infusions with aggressive physical and occupational rehabilitation is essential for re-educating neural pathways.

Schedule a Comprehensive Medical Review

Whether you are exploring options under the domestic Right to Try pathway or looking into international clinical programs, our clinical team provides complimentary, thorough evaluations of your medical history.

Toll-Free Helpline: +1 (844) GET-STEM

Email: info@r3stemcell.com

Inquiries: Schedule your free medical consultation with an R3 clinical advisor today.

Contact Us

Email: info@r3stemcell.com